Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1HR+/HER2- Advanced Breast Cancer 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

Fulvestrant 8olaparib 4Capecitabine 4pyrotinib 3Docetaxel 3toripalimab 2Vinorelbine 2Trastuzumab 2Letrozole 2Injections 2Goserelin 2Alpelisib 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1sacituzumab govitecan 1pembrolizumab 1neratinib 1liposomal doxorubicin 1exemestane 1eribulin 1dalpiciclib 1ceralasertib 1cediranib 1capivasertib 1abemaciclib 1Tablets 1Paclitaxel 1Moxifloxacin 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Cancer × dalpiciclib × Clear all
NCT05431504 2022-06-24

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
53 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡